Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - News - Front Page Healthcare News - September 19, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/19/17 - $1.2 Bn Stationary Oxygen Concentrators Market, 2023
The "Stationary Oxygen Concentrators: Market Shares, Strategies, and Forecasts, Worldwide 2017- 2023" report from Wintergreen Research, Inc has been added to Research and Markets' offering. Stationary oxygen concentrator markets at $725.5 million market in 2016 are set to become a $1.2 billion market in 2023. Steady growth is anticipated because th
9/19/17 - 'DNA Day' planned for Ravens' game undergoes federal and state scrutiny [The Baltimore Sun]
The federal agency said Monday that Boston- based Orig3n may be required to obtain federal certification to conduct such testing. The agency, part of the U.S. Department of Health and Human Services, said in a statement that it is "working to determine whether any of the testing being offered by Orig3n is subject to the requirements of the Clinical
9/19/17 - 3 Barriers Between the New GOP ACA Bill and Trump's Desk [LifeHealthPro]
Whether Republicans can pass the big new GOP Affordable Care Act change bill, the Graham-Cassidy-Heller-Johnson bill, in time to affect 2018 will depend on whether the most conservative Republicans in Congress, and the most moderate Republicans in Congress, can close their eyes, hold their noses and control their stomachs long enough to vote for th
9/19/17 - ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 10:00 a.m. Eastern Time i
9/19/17 - ACCELERON PHARMA INC FILES (8-K) Disclosing Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 18, 2017, Acceleron Pharma Inc. and Celgene Corporation entered into an Amended and Restated Collaboration, License and Option Agreement that amends and restates their existing Collaboration, License and Option Agreement, dated as of February 20, 2008 and amended as of August 2, 201
9/19/17 - Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it has amended the sotatercept development and commercialization collaboration agreement with Celgene Corporation, originally executed on February 20, 2008. Sotatercept shows...
9/19/17 - AccessOne and East Texas Medical Center Partner to Provide Financing Options to Patients
We are excited about reaching a full range of patients and people throughout ETMC s community, said David White, executive vice president of business development of AccessOne. With this new addition, ETMC is able to provide one financial platform benefiting an entire system.. Through AccessOne s flexible patient financing options,
9/19/17 - Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company, today announced that results from a Phase 2 clinical trial evaluating two concentrations of its drug candidate A-101 for the treatment of facial seborrheic keratosis lesions have been published in the journal Dermatologic Surgery. The FDA s Prescription Drug User Fee Ac
9/19/17 - AgeneBio Receives NIH Grant to Initiate Phase 3 HOPE4MCI Trial to Treat MCI Due to Alzheimer's Disease
This grant builds on the previous NIH grant for the HOPE4MCI trial that established a public-private partnership among the NIA, Johns Hopkins University, and AgeneBio for the HOPE4MCI trial. "With the award of this additional funding from the NIH, we will immediately initiate the Phase 3 trial start-up with an initial cohort of clinical sites and
9/19/17 - Agilent Announces Expanded Use of Cancer Diagnostic in the United States
Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The PDL1 IHC 28-8 pharmDx test enables physicians in the USA to identify which patients with locally adv
9/19/17 - Agilent Announces Expanded Use of Cancer Diagnostic in the United States; .Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications
SANTA CLARA, Calif. Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The PDL1 IHC 28-8 pharmDx test enables physicians in the USA to identify which pat
9/19/17 - Agilent Obtains U.S. FDA Approval for GenetiSure Dx Postnatal Assay
SANTA CLARA, Calif.- Agilent Technologies Inc. has announced that it has obtained 510 clearance from the U.S. Food and Drug Administration for the GenetiSure Dx Postnatal Assay: its first comparative genomic hybridization assay for diagnostic use. Previously available only in Europe, U.S. clinical genetic scientists can now use this assay to help i
9/19/17 - Airway Management Devices Market: Estimated to Flourish by 2025
The global airway management devices are medical devices used for patients have obstructed airways or are at the risk of being obstructed.San Francisco, CA 09/18/2017 Global Airway Management Devices Market: Overview The global airway management devices are medical devices used for patients have obstructed airways or are at the risk of being
9/19/17 - Amgen and Allergans anti-cancer biosimilar Mvasi receives FDA approval [All Iraq News Agency (AIN)]
Co-developed by Amgen and Allergan, Mvasi is the first anti-cancer biosimilar to be approved by the FDA and is largely similar to Avastin. Amgen research and development executive vice-president Dr Sean E. Harper said: The approval of Mvasi marks a significant milestone for healthcare practitioners and patients as the first anti-cancer biosimilar..
9/19/17 - AMICUS THERAPEUTICS INC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On September 19, 2017, Amicus Therapeutics, Inc. issued a press release announcing that the U.S. FDA has granted Fast Track Designation for Amicus Therapeutics' Migalastat for Treatment of Fabry Disease. A copy of this press release is attached hereto as Exhibit 99.1. Description 99.1 Press Release dated September 19, 2017 titled " U.S. FDA Grants
9/19/17 - Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis. The Company recently began a Phase 2 clinical study, the CENTAUR trial, to evaluate the safety and efficacy of AMX003
9/19/17 - AP Top Health News at 11:12 a.m. EDT
The Latest: McConnell praises new effort to repeal Obamacare Senate leader praises revived GOP health law repeal drive Study: 4,500 deaths a year from high Europe diesel emissions City asks judge to let case against OxyContin maker proceed Christie: Drugmakers to work on nonaddictive pain medication Suicide among veterans highest in western US, rur
9/19/17 - AP Top Health News at 11:53 a.m. EDT
The Latest: McConnell praises new effort to repeal Obamacare Senate leader praises revived GOP health law repeal drive FDA OKs Glaxo's inhaler, first one to combine 3 medicines Study: 4,500 deaths a year from high Europe diesel emissions City asks judge to let case against OxyContin maker proceed Christie: Drugmakers to work on nonaddictive pain me
9/19/17 - AP Top Health News at 12:02 p.m. EDT
The Latest: McConnell praises new effort to repeal Obamacare Senate leader praises revived GOP health law repeal drive FDA OKs Glaxo's inhaler, first one to combine 3 medicines States expand investigation of opioid makers, distributors Study: 4,500 deaths a year from high Europe diesel emissions City asks judge to let case against OxyContin maker p
9/19/17 - APHA Strongly Opposes Latest Effort to Overturn Affordable Care Act
The American Public Health Association issued the following news release:. The American Public Health Association announced its strong opposition to the Graham-Cassidy bill, the latest attempt to repeal the Affordable Care Act, in a letter sent to the Senate today. "Consistent with previous proposals, the Graham-Cassidy plan would also eliminate t
9/19/17 - Apollo Endosurgery to Present at the Cantor Fitzgerald Global Healthcare Conference
Apollo Endosurgery, Inc., a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that company management is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26 at 9:10 am Eastern in New York, NY. Investors attending the conference who would like to sch
9/19/17 - Archway Examines the Impact of Bundled Payments Ahead of Expected New CMS Programs
According to a survey conducted by Archway Health a Boston- based firm specializing in managing bundled payments programs participation in bundled payments has improved the quality of care, and anticipation and preparation for new programs remains high. The survey assessed the perceptions and efficacy of bundled payments ahead of the expected
9/19/17 - Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, will hold a conference call to discuss an update on the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of...
9/19/17 - Arkis BioSciences Achieves FDA Clearance of its CerebroFlo? EVD Catheter with Endexo Technology
Arkis BioSciences, a leading innovator in minimally invasive surgical instrumentation, has obtained FDA clearance of its new external ventricular drainage catheter, CerebroFlo?. Seaver says Arkis plans to introduce the device to the U.S. market at the upcoming annual Congress of Neurological Surgeons, which will be held in Boston, MA, Oct. 7-11
9/19/17 - ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations,
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415